EGFR and non-small cell lung carcinoma: Based on this preclinical evidence, a clinical trial to evaluate the safety and efficacy of the first‐line treatment with AXL inhibitor ONO7475‐03 and osimertinib in EGFR mutated NSCLC patients (jRCT2051210045) is currently ongoing.